Navigation Links
China Sky One Medical, Inc. Announces Record First Quarter 2009 Results

HARBIN, China, May 14 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced record financial results for the first quarter of 2009.

    First Quarter 2009 Highlights
    -- Total revenues doubled year-over-year to $24.8 million
    -- Gross profit increased 96.7% year-over-year to $18.8 million
    -- Operating income increased 86.1% to $9.1 million from $4.9 million a
       year ago
    -- Net income increased 87.4% year-over-year to $7.2 million, or $0.43 per
       diluted share
    -- Received SFDA approval to manufacture Calcium Folinate injection and
       Policresulen vaginal suppositories
    -- Received SFDA approval to enter into clinical trials for two new
       traditional Chinese medicines, Paeonol gel and Mei Lu gel
    -- Expanded the sale of its best-selling Sumei Slim Patch into South Korea
       and Sudan
    -- Signed an exclusive distribution agreement with Shaanxi Buchang Group
       for Naftopidil dispersible tablets with an expected sales target of
       $14.6 million over five years

"We are pleased to report another quarter of excellent results to start off 2009. We achieved record financial performance in the first quarter with strong increases in revenue and net income as we executed our business strategy and further established ourselves as a leading pharmaceutical company in China," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical, Inc. "We continued to refine and enhance our distribution channels during the quarter and signed several distribution agreements for our products and expanded sales of our top-selling Sumei Slim Patch into South Korea and Sudan."

First Quarter 2009 Results

Total revenues doubled year-over-year to $24.8 million for the three months ended March 31, 2009. The increase was primarily attributable to the strong performance by the Company's sales agents as well as contributions from several successful business acquisitions in 2008. Sales of patch products, including its best-selling Sumei Slim Patch, rose 141% to $9.1 million in the first quarter of 2009, and accounted for 37% of revenue, up from 30% a year ago. Sales of ointments rose 242% year over year to $5.1 million, accounting for 20% of revenue, compared to 12% of revenue a year ago. Sprays and Bio-engineering products, including the Company's line of diagnostic testing kits, rose 55% and 70%, respectively, each accounting for 12% of revenue during the quarter. In keeping with its strategic goals, the Company decreased contract sales of non-manufactured products in 2008 in order to focus on higher margin proprietary products. Contract sales of non-manufactured products were discontinued in the three months ended March 31, 2009.

Gross profit in the first quarter of 2009 was $18.8 million, an increase of 97% over the same period a year ago. Gross margin was 76% of total revenues, a slight decrease compared to gross margin of 77% for the first quarter of 2008. The decrease was attributable to lower unit selling prices, by which the Company expects to maintain its competitiveness. The Company was able to negotiate lower purchase prices from its suppliers, which offset the decline in selling prices.

Operating expenses in the first quarter of 2009 were $9.7 million, up 107.1% from $4.7 million in the first quarter of 2008. The increase was mainly the result of higher selling, general and administrative expenses, which were primarily attributable to the increased costs of marketing our products, and higher research and development expenses, primarily due to additional clinical trials for its products and the development of patents to generate continued sales growth.

Operating income was $9.1 million for the first quarter of 2009, representing an 84.5% increase from $4.9 million in the first quarter of 2008. Operating margin was 36.4%, compared to 39.1% in the first quarter of 2008.

Provision for income taxes was $1.8 million in the first quarter of 2009, compared to $1.0 million in the same period last year.

Net income for the first quarter of 2009 was $7.2 million, or $0.43 per diluted share, compared to net income of $3.9 million, or $0.26 per diluted share, in the first quarter of 2008. Diluted earnings per share was calculated using a weighted average share count of 16.7 million in the first quarter of 2009, compared to 14.9 million a year ago.

Financial Condition

As of March 31, 2009, China Sky One had $48.8 million in cash and cash equivalents, approximately $65.9 million in working capital, and no debt. Stockholders' equity at March 31, 2009, was $102.3 million, a 7.8% increase over the $94.9 million recorded at December 31, 2008.

The Company generated $8.5 million in net cash flow from operating activities in the first quarter of 2009, up from $5.2 million in the corresponding period of 2008.

The Company is currently constructing a new corporate headquarters which will be completed in 2009 at an additional estimated cost of approximately $5 million. The Company plans to fund the project using internally generated funds.

Recent Events

On April 23, 2009, the Company announced that it obtained approvals from the State Food and Drug Administration (SFDA) in China for the production of Geranium ointment and Musk liniment for pain relief. The two products are estimated to contribute $0.8 million to revenues in 2009 and potentially much more in 2010.

As of May 4, 2009, the Research & Development project for the Company's Sudden Cardiac Death (SCD) Early Examination Kit had been appraised by the Heilongjiang Bureau of Science and Technology. This project represents one of the very few proprietary technologies in the bio-diagnostic field that is owned by the Chinese. Management expects to complete the new product application process within one year.

Business Outlook and Guidance

"We are confident about the prospects for our business in 2009 and will continue to focus on increasing market share by both strengthening and further refining our successful sales and distribution network, building and enhancing our brand image, and making strategic acquisitions that continue to support our growth," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical, Inc.

"In 2009, we expect full year revenue to increase by 40%, or approximately $37.0 million, to $128-$130 million, driven by growth in all of our product sales categories. We expect that net income will increase to $38-$39 million, resulting in net profit margin of approximately 30%. We expect 2009 gross margin to be approximately 74% due to higher raw material costs," Mr. Yan-Qing Liu added.

Conference Call

The Company will conduct a conference call at 10:00 a.m. Eastern Daylight Time on Friday, May 15, 2009, to discuss its first quarter of fiscal year 2009 financial results. Joining Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical, Inc., will be Stanley Hao, Chief Financial Officer.

To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (888) 419-5570. International callers should call (617) 896-9871. The Conference Passcode is 455 090 46. If you are unable to participate in the call at that time, replay of the conference call will be available from Friday, May 15, 2009 at 12:00 p.m. Eastern until Friday, May 29, 2009. To access the replay, call (888) 286-8010. International callers should call (617) 801-6888. The Conference Replay Passcode is 464 826 92.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio- Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

                           Financial Statements Below

                 China Sky One Medical, Inc. and Subsidiaries
       Condensed Consolidated of Income and Other Comprehensive Income
              For the Three Months Ended March 31, 2009 and 2008

                                                 Three Months Ended March 31,
                                                      2009           2008
                                                   Unaudited      Unaudited

    Revenues                                    $  24,833,692  $  12,413,430
    Cost of Goods Sold                              6,040,918      2,860,428
    Gross Profit                                   18,792,774      9,553,002

    Operating Expenses
     Selling, general and administrative            6,877,468      3,956,795
     Depreciation and amortization                    451,372         76,348
     Research and development                       2,412,780        669,833
      Total operating expenses                      9,741,620      4,702,976

    Other Income (Expense)
     Other income                                          --         63,048
     Interest expense                                  11,823         (1,147)
      Total other income (expense)                     11,823         61,901

    Net Income Before Provision for Income Tax      9,062,977      4,911,927

    Provision for Income Taxes
     Current                                        1,820,139      1,047,016

    Net Income                                      7,242,838      3,864,911

    Basic Earnings Per Share                             0.44           0.28
    Basic Weighted Average Shares Outstanding      16,413,920     13,732,269

    Diluted Earnings Per Share                           0.43           0.26
    Diluted Weighted Average Shares Outstanding    16,665,221     14,888,310

    Comprehensive Income
     Net Income                                     7,242,838      3,864,911
     Foreign currency translation adjustment          116,942      1,620,516

    Comprehensive Income                            7,359,780      5,485,427

                 China Sky One Medical, Inc. and Subsidiaries
                    Condensed Consolidated Balance Sheets

                                                     March 31,   December 31,
                                                        2009         2008
                                                    (Unaudited)   (Audited)
    Current Assets
     Cash and cash equivalents                      $48,788,597  $40,288,116
     Accounts receivable, net                        14,077,827   14,978,648
     Inventories                                      1,320,295      462,351
     Prepaid and other current assets                    77,726      106,386
     Land and construction deposit                    8,523,979    8,513,284
      Total current assets                           72,788,424   64,348,785

    Property and equipment, net                      20,907,074   21,058,779
    Intangible assets, net                           15,531,498   15,851,765
                                                   $109,226,996 $101,259,329


    Current Liabilities
     Accounts payable and accrued expenses          $ 3,702,703  $ 2,937,068
     Taxes payable                                    3,202,051    3,362,888
     Deferred revenues                                       --       26,079
      Total current liabilities                       6,904,754    6,326,035

    Commitments and Contingencies

    Stockholders' Equity
     Preferred stock ($0.001 par value, 5,000,000
      shares authorized, none issued and outstanding)        --           --
     Common stock ($0.001 par value, 50,000,000
      shares authorized, 16,446,467 and 16,306,184
      issued and outstanding, respectively)              16,446       16,306
     Additional paid-in capital                      40,134,162   40,105,134
     Accumulated other comprehensive income           5,683,748    5,566,806
     Retained earnings                               56,487,886   49,245,048
      Total stockholders' equity                    102,322,242   94,933,294
                                                   $109,226,996 $101,259,329

                 China Sky One Medical, Inc. and Subsidiaries
               Condensed Consolidated Statements of Cash Flows

                                                  Three Months Ended March 31,
                                                      2009           2008
    Cash flows from operating activities
     Net Income                                  $ 7,242,838    $ 3,864,911
     Adjustments to reconcile net cash
      provided by operating activities
      Depreciation and amortization                  588,066        140,009
      Share-based compensation expense                    --         10,117
     Net change in assets and liabilities
      Accounts receivables                           912,487      1,859,639
      Inventories                                   (857,238)      (408,079)
      Prepaid expenses and other current assets       35,805          5,526
      Accounts payable and accrued expenses          735,730       (370,378)
      Taxes payable                                 (165,038)       102,786
      Deferred revenues                                   --         (6,952)
    Net cash provided by operating activities      8,492,650      5,197,579

    Cash flows from investing activities
     Purchases of fixed assets                       (66,148)       (42,782)
     Land and construction deposit                        --       (710,656)
     Purchase of subsidiary-Heilongjiang Haina
      Pharmaceutical, Inc.                                --       (427,838)
     Cash of subsidiary upon acquisition                  --         82,715
     Purchase of intangible assets                    (3,651)        (7,139)
    Net cash used in investing activities            (69,799)    (1,105,700)

    Cash flows from financing activities
     Sale of common stock for cash, net of
      offering costs                                      --     23,487,963
     Proceeds from warrants conversion                29,169        739,588
    Net cash provided by financing activities         29,169     24,227,551

    Effect of exchange rate changes on cash           48,462        727,694

    Net increase in cash and cash equivalents      8,500,481     29,047,124

    Cash and cash equivalents at
     beginning of period                          40,288,116      9,190,870

    Cash and cash equivalents at end of period   $48,788,597    $38,237,994

    Supplemental disclosure of cash flow
    Interest paid                                $        --    $     1,157
    Taxes paid                                   $ 2,106,956    $   944,230

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Yu-Bo Hao, CFO
     Tel:   +86-451-5399-4069

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915

SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. China Medicine Announces First Quarter 2009 Results
2. Winner Medical Establishes Joint Venture With West China Hospital in Chengdu, China
3. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
4. China Nepstar Chain Drugstore to Announce First Quarter 2009 Financial Results on Wednesday, May 27, 2009
5. New study reveals the financial effects of stroke in China
6. China Pharma Holdings, Inc. to Report First Quarter 2009 Financial Results on May 15, 2009
7. China Medicine Announces Conference Call to Discuss First Quarter 2009 Results
8. China Medicine to Present at CCG IRs China Rising Conference in New York
9. IBM Announces New Healthcare Industry Solutions Lab in China
10. Solta Medical Receives Regulatory Approval to Market Thermage Systems in China
11. China Pharma Holdings, Inc. Retains Global Investor Communications Team
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... Consultants has prided itself for not only fulfilling the needs of advisers and ... at an affordable price and providing top-tier customer service. However, there's always room ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... They observed that both STEMI and Sepsis conditions present in similar ways and require ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into ... Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that ...
(Date:11/26/2015)... NV (PRWEB) , ... November 26, 2015 , ... Inevitably ... strategy. Many customers choose to buy during the Black Friday and Cyber Monday ... Shoppers don’t need to search the Internet high and low to find the best ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Bajos, November 26, 2015 Un ... de Bremachlorin para el cáncer avanzado.   ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Cancer Research . --> Clinical Cancer Research ...
(Date:11/26/2015)... , November 26, 2015 --> ... to use SyMRI to find optimal contrast weighting of MRI ... metastases, and has signed a research agreement with SyntheticMR in ... hospital. Using SyMRI, it is possible to generate multiple contrast ... after the patient has left, thus making it possible to ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology: